SP 1.1.2 - A System For All Day Biosampling: Microdialysis and Wearables Collide

Event

EUROSENSORS 2026
2026-09-06 - 2026-09-09
Zurich

Band

Lectures

Chapter

Continuous Health Monitoring in Medicine

Author(s)

T. Upton - University of Bristol,Bristol (UK), E. Zavala, S. Lightman and the ULTRADIAN consortium - University of Manchester,Manchester (UK), P. Methlie - University of Bergen,Bergen (Norway), M. van Faassen - University Medical Center Groningen,Groningen (Netherlands)

Pages

278 - 279

DOI

10.5162/eurosensors2026/SP1.1.2

ISBN

978-3-910600-12-6

Price

free

Abstract

Primary aldosteronism affects 5–20% of the hypertensive population and is associated with increased cardiovascular and metabolic risk compared with primary hypertension. Alterations in the dynamics of aldosterone secretion are key, but these are not well captured by current diagnostic pathways, and the disease is often missed. In this proof-of-concept study, we utilized ambulatory microdialysis sampling to continuously monitor tissue corticosteroid dynamics in primary aldosteronism over 24 hours. In a cohort of 60 patients, we found prominent and pulsatile nocturnal hypersecretion of aldosterone and the hybrid steroids 18hydroxycortisol and 18-oxocortisol with a preserved daily rhythm. This was most prominent in unilateral disease, with normalization after adrenalectomy. Our findings confirm that a key pathophysiological feature of primary aldosteronism is disruption of corticosteroid rhythms, rather than persistent elevation of hormones. We show that ambulatory dynamic hormone profiling is a viable technique that offers substantially more information than current diagnostic approaches relying on single time-point hormone measurements. In the future this offers the opportunity to investigate more subtle dynamic phenotypes and potentially earlier detection of disease.